Entresto access in Saudi Arabia: the SFDA named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Entresto (sacubitril/valsartan) is the first member of the angiotensin receptor neprilysin inhibitor class, an oral fixed-dose combination that reduces cardiac wall stress in chronic heart failure. It is FDA-approved for chronic heart failure across a range of ejection fractions, with the strongest evidence in heart failure with reduced ejection fraction (HFrEF), and a pediatric indication for patients aged one year and older with symptomatic heart failure due to systemic left ventricular dysfunction. In the Kingdom of Saudi Arabia, Entresto is registered with the Saudi Food and Drug Authority through Novartis Saudi Arabia. Demand for the SFDA Personal Importation Program centers on stocking continuity at the 97/103 mg target dose, pediatric dosing in weight-appropriate strengths, and Saudi cardiology patients returning from US or EU treatment who want to maintain US-origin Novartis-manufactured Entresto. Reserved for you.

Why patients in Saudi Arabia need Entresto via NPP

Entresto is a globally registered cardiology product rather than a rare-disease orphan therapy, and SFDA registration through Novartis Saudi Arabia means the medicine is on the Kingdom register. The named-patient demand pattern is driven by supply continuity rather than first-access. Three patterns recur. First, stocking gaps in secondary cities and across the three strengths. Entresto registration in Saudi Arabia does not guarantee that every pharmacy carries the 24/26 mg, 49/51 mg, and 97/103 mg strengths consistently, and a fully titrated HFrEF patient on the 97/103 mg twice-daily target dose may find their local pharmacy can supply the lower strengths reliably but not the target dose. Second, branded-Entresto preference. Some Saudi cardiology patients who initiated therapy in the US, the UK, or the EU and have since returned to the Kingdom want to remain on US-manufactured Novartis Entresto rather than rotate to another locally available presentation. Third, pediatric supply. The October 2019 pediatric indication for patients aged one year and older introduced weight-based dosing that is not consistently stocked across all institutions, and pediatric cardiology programs at KFSH&RC and KAMC sometimes need named-patient supply to bridge a titration window. None of these is a regulatory contraindication; SFDA PIP is the lawful corridor.

The SFDA Personal Importation Program for Entresto

The SFDA Personal Importation Program allows a SCFHS-licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognised reference authority (US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally available alternative is not suitable. Entresto qualifies under the reference-authority test: FDA-approved July 2015 for adult HFrEF, expanded February 2021 to chronic heart failure across ejection fractions, with the pediatric indication added October 2019. EMA marketing authorisation has been in place since November 2015. The clinical-equivalence test is met when the case is one of supply continuity, branded-product preference for a patient previously stabilised on US-manufactured Entresto, or pediatric dosing not supplied locally.

The clinical-justification angle in an Entresto PIP file typically anchors on one of three patterns. For an adult HFrEF patient already titrated to 97/103 mg twice daily, the letter documents the heart failure diagnosis with NYHA class and ejection fraction, the response to the target Entresto dose, and the operational reason a domestic alternative is not suitable (continuity from prior US care, target-dose stocking gap, or specific patient response history). For a chronic-heart-failure patient across the broader ejection-fraction range, the letter references the 2021 expanded indication and the patient's individual hemodynamic and renal profile. For a pediatric patient aged one year or older with systemic left-ventricular dysfunction, the letter documents the pediatric heart failure diagnosis, weight, and the package-insert pediatric dosing table, alongside the dispensing institution's pediatric cardiology capability.

A complete application includes the clinical justification letter on institutional letterhead, the treating physician's active Saudi Commission for Health Specialties (SCFHS) license in cardiology, pediatric cardiology, or internal medicine, an anonymised patient identifier, full product details (brand Entresto, generic sacubitril/valsartan, manufacturer Novartis, strength 24/26 mg, 49/51 mg, or 97/103 mg, film-coated tablet, pack size, lot, expiry, requested quantity), DSCSA pedigree documentation confirming authorised US distribution channel, the destination dispensing facility SFDA license, and a chain-of-custody plan. Because Entresto is a room-temperature oral tablet, the chain-of-custody plan is simpler than for a cold-chain biologic, but it still documents authorised US distributor sourcing under T3 transaction history rules, sealed-blister integrity, humidity protection through hot-climate transit, and minimum remaining shelf-life on arrival. Routine cases run 10 to 21 business days through SFDA review; complex cases extend to 6 to 10 weeks.

Where Entresto gets dispensed in Saudi Arabia

Entresto is a film-coated oral tablet that does not require cold-chain storage, infusion-suite administration, or self-injection training. The dispensing facility list is therefore the broadest in the Reserve Meds matrix: any SFDA-licensed pharmacy attached to a hospital with a cardiology service line or a pediatric cardiology service line can dispense. The cardiology programs at King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Jeddah, and Madinah handle adult and pediatric heart failure with established import-pharmacy workflow. King Abdulaziz Medical City and the Ministry of National Guard Health Affairs network in Riyadh and Jeddah, King Saud University Medical City, and the private networks Dr. Sulaiman Al Habib Medical Group, Saudi German Hospital, Dr. Soliman Fakeeh Hospital, and Dallah Hospital all run cardiology outpatient pharmacies that can receive PIP-imported product.

For a patient in the Eastern Province, Tabuk, Asir, Madinah outside the KFSH campus, or another region without an in-house import pharmacy, the standard route is an SFDA-licensed specialty importer in Riyadh or Jeddah filing the PIP application on behalf of the prescribing physician, clearing the shipment through customs, and transferring under institutional license to the dispensing facility. Ambient shipping with summer-heat protection makes the cross-country last-mile logistics straightforward.

Real cost picture for Entresto in Saudi Arabia

US wholesale acquisition cost for Entresto is approximately USD 12.50 per day across the three strengths at standard payer references, equating to roughly USD 4,500 per year at WAC for daily dosing. US cash-pay retail without insurance is approximately USD 600 to 700 per 30-day supply (USD 7,200 to 8,400 per year). The Saudi riyal is pegged at approximately 3.75 SAR to 1 USD, so a year of Entresto at US WAC translates to approximately SAR 17,000 before any logistics, customs, or coordination overhead. The 2026 Medicare Part D Maximum Fair Price (USD 295 per 30-day supply) applies only to Medicare beneficiaries inside the United States and is not available for international named-patient procurement.

The all-in delivered-to-Saudi cost typically includes US drug acquisition at WAC, ambient international logistics in the SAR 750 to 2,250 (USD 200 to 600) range depending on supply window and destination city, SFDA regulatory documentation handling, customs clearance, and the Reserve Meds coordination fee. Because Entresto is a room-temperature oral tablet, three- and six-month supply windows are operationally simple and reduce per-month logistics overhead.

On the insurer side, Bupa Arabia, Tawuniya, and MedGulf Arabia each handle named-patient imports case by case under CCHI plan-structure rules. Heart failure care is broadly covered in Saudi private and employer-sponsored plans, but PIP-routed Entresto imports may be assessed against the locally registered alternative. Cash-pay is the default operating posture; reimbursement is sought after delivery where the plan permits. Reserve Meds quotes an indicative range at intake and a firm itemised quote after documentation review.

Typical timeline for Entresto in Saudi Arabia

From waitlist submission to first 90-day supply in hand, the typical Entresto case in Saudi Arabia runs as follows. Reserve Meds confirms eligibility within 24 to 48 hours and sends a documentation kit to the treating physician. The physician or hospital import pharmacy or SFDA-licensed importer files the PIP application, which clears in 10 to 21 business days for routine cases. In parallel, Reserve Meds confirms US-side specialty pharmacy sourcing, DSCSA pedigree, and minimum remaining shelf-life dating. Once SFDA approval is issued, US release and ambient shipment add 5 to 7 business days plus customs clearance. The full cycle for an initial 90-day supply is typically 3 to 5 weeks, faster than comparable cold-chain biologic cases because of the simpler logistics profile. Re-supply aligns with the cardiologist's regular review cadence at 2 to 4 weeks during titration and 3 to 6 months once on maintenance dosing.

What your physician needs to provide

The clinical justification letter is the cornerstone of the SFDA PIP package for Entresto. On institutional letterhead, signed by a SCFHS-licensed physician in cardiology, pediatric cardiology, or internal medicine, the letter typically includes diagnosis with ICD-10 coding (chronic heart failure with reduced or preserved ejection fraction, pediatric heart failure with systemic left-ventricular dysfunction, or the combination relevant to the case), severity markers including NYHA functional class, ejection fraction, eGFR, baseline blood pressure, and serum potassium, the prior-therapy history (ACE inhibitor or ARB tolerability, current beta-blocker, MRA, and SGLT2 inhibitor stack), the rationale for ARNI therapy now, the rationale for branded Novartis-manufactured Entresto specifically (continuity from prior US care, pediatric weight-based dosing, or local stocking gap at the target dose), the proposed dosing plan (starting at 49/51 mg twice daily in patients previously tolerating moderate-to-high doses of an ACE inhibitor or ARB, or 24/26 mg twice daily in lower-dose, lower-eGFR, or hepatic-impairment cases, with titration every 2 to 4 weeks to the 97/103 mg twice-daily target; pediatric dosing per weight-band table), the 36-hour ACE-inhibitor washout protocol where applicable, and the monitoring plan including blood pressure, eGFR, serum potassium, and angioedema surveillance.

The contraindication of concurrent ACE-inhibitor use and the angioedema warning are addressed explicitly in the letter, with the 36-hour washout protocol documented for any patient transitioning from an ACE inhibitor. The physician confirms their SCFHS license is active for the full requested treatment course.

Common questions about Entresto in Saudi Arabia

Will Bupa Arabia, Tawuniya, or MedGulf cover Entresto?

Each insurer assesses heart failure named-patient imports case by case. Where the medicine is on the insurer's formulary, reimbursement is more likely; where it is not, pre-authorisation with the clinical justification letter is typically required. We supply the documentation that lets the insurer assess; the claim is yours or your hospital's to file. Cash-pay is the default operating posture.

Will my SCFHS-licensed cardiologist's letter be sufficient?

Yes. SCFHS-licensed cardiologists, pediatric cardiologists, and internal medicine specialists at KFSH&RC, KAMC, MNGHA, KSUMC, and the major private networks have full signing authority on PIP applications for Entresto. The institutional pharmacy license authorises the dispensing facility to receive the imported tablets.

Is Entresto appropriate for pediatric patients?

The FDA-approved pediatric indication covers patients aged one year and older with symptomatic heart failure due to systemic left-ventricular dysfunction. Dosing is weight-based per the package insert table, starting at lower mg/kg doses and titrating upward over two weeks as tolerated. KFSH&RC, KAMC, and the major academic centers run pediatric cardiology programs equipped to manage Entresto initiation and titration. Compounded oral suspensions for very young children unable to swallow tablets are possible per the package insert but are an institutional pharmacy decision.

Can Entresto be combined with my current heart failure medications?

Entresto is used alongside beta-blockers, mineralocorticoid receptor antagonists (spironolactone, eplerenone), and SGLT2 inhibitors (dapagliflozin, empagliflozin) as part of guideline-directed medical therapy. It must not be combined with an ACE inhibitor; a 36-hour washout is required when switching to or from an ACE inhibitor to reduce angioedema risk. Combination with aliskiren is contraindicated in patients with diabetes or renal impairment. Pregnancy is contraindicated.

What is the safety profile for Entresto?

The most frequent adverse events in PARADIGM-HF were hypotension, hyperkalemia, cough, dizziness, and renal impairment. Angioedema occurred at a low rate (0.1 to 0.5 percent) with higher incidence in Black patients. Discontinuation rates for adverse events were comparable to enalapril. Symptoms of angioedema (facial, lip, tongue, or airway swelling) require immediate discontinuation and urgent medical attention.

How is the response to Entresto monitored?

Baseline and periodic monitoring of blood pressure, serum creatinine and eGFR, and serum potassium is standard. More frequent monitoring is appropriate during dose titration, in patients with chronic kidney disease, in patients on potassium-sparing diuretics or supplements, and in elderly patients. Reassessment is typically at 2 to 4 weeks during titration and at 3 to 6 month intervals once at maintenance dose.

Where Reserve Meds fits in Entresto cases

Reserve Meds is a US-based concierge coordinator. We do not replace the treating cardiologist, do not replace SFDA, and do not replace the Saudi dispensing pharmacy. What we do is orchestrate US-side specialty pharmacy sourcing of authorised Novartis-manufactured Entresto with full DSCSA pedigree, prepare the regulatory documentation kit the treating physician needs, coordinate ambient international logistics with summer-heat protection through hot-climate transit, and assign a single named coordinator through the case and through quarterly re-supply. The Entresto case pattern aligns with chronic-therapy maintenance: simple logistics, predictable re-supply, and case-management cadence that mirrors the cardiologist's review schedule. Three Reserve Meds case patterns recur for Entresto in Saudi Arabia: the patient stabilised on US-titrated 97/103 mg twice daily returning home and seeking continuity, the pediatric heart failure patient at KFSH&RC or KAMC needing weight-appropriate Novartis-manufactured supply, and the snowbird patient who maintains primary residence in Saudi Arabia with extended US family ties. No prior Reserve Meds dispensed-case experience as of this page; standard NPP coordination applies.

Next step

If the cardiologist or pediatric cardiologist has recommended Entresto and Saudi pharmacy supply is not aligned with the prescription, the waitlist is the first step. We confirm eligibility within 24 to 48 hours and send the physician documentation kit.

Reserved for you.

---

This guide is informational, not medical or legal advice. The SFDA Personal Importation Program requires a SCFHS-licensed physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.